27629 Malignancy rates through 4 years of follow-up in guselkumab-treated moderate to severe psoriasis patients from the VOYAGE 1 and 2 trials and comparisons to the general United States population

Abstract

Objective: To summarize the incidence of malignancies by NMSC and malignancies other than NMSC/cervical cancer in situ, using pooled VOYAGE1&2 data through 4-years of guselkumab (GUS) treatment; results were compared with expected rates in the general USpopulation.